- Home
- CRSP vs SIGI Comparison
CRSP vs SIGI Comparison
Compare CRSP & SIGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- SIGI
- Stock Information
- Founded
- CRSP 2013
- SIGI 1926
- Country
- CRSP Switzerland
- SIGI United States
- Employees
- CRSP N/A
- SIGI N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- SIGI Property-Casualty Insurers
- Sector
- CRSP Health Care
- SIGI Finance
- Exchange
- CRSP Nasdaq
- SIGI Nasdaq
- Market Cap
- CRSP 5.6B
- SIGI 4.7B
- IPO Year
- CRSP 2016
- SIGI N/A
- Fundamental
- Price
- CRSP $52.57
- SIGI $78.38
- Analyst Decision
- CRSP Buy
- SIGI Hold
- Analyst Count
- CRSP 19
- SIGI 5
- Target Price
- CRSP $71.94
- SIGI $80.50
- AVG Volume (30 Days)
- CRSP 2.5M
- SIGI 619.7K
- Earning Date
- CRSP 11-10-2025
- SIGI 10-22-2025
- Dividend Yield
- CRSP N/A
- SIGI 2.19%
- EPS Growth
- CRSP N/A
- SIGI 74.66
- EPS
- CRSP N/A
- SIGI 6.49
- Revenue
- CRSP $38,337,000.00
- SIGI $5,228,435,000.00
- Revenue This Year
- CRSP N/A
- SIGI $4.78
- Revenue Next Year
- CRSP $391.94
- SIGI $4.28
- P/E Ratio
- CRSP N/A
- SIGI $12.09
- Revenue Growth
- CRSP N/A
- SIGI 10.87
- 52 Week Low
- CRSP $30.04
- SIGI $71.75
- 52 Week High
- CRSP $78.48
- SIGI $103.56
- Technical
- Relative Strength Index (RSI)
- CRSP 34.88
- SIGI 49.58
- Support Level
- CRSP $52.42
- SIGI $73.46
- Resistance Level
- CRSP $58.48
- SIGI $80.05
- Average True Range (ATR)
- CRSP 3.56
- SIGI 1.64
- MACD
- CRSP -1.14
- SIGI 0.39
- Stochastic Oscillator
- CRSP 21.64
- SIGI 76.19
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About SIGI Selective Insurance Group Inc.
Selective Insurance Group Inc is a regional property-casualty insurer based in New Jersey, with its operations focused in the New York metropolitan area. The Company has four operating segments: Standard Commercial Lines, Standard Personal Lines, E&S Lines, Investments. Majority of revenue is gained from Standard Personal Lines. Currently company has it's revenues from States of USA and Columbia.